Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer

Soo Young Kim, Seok Mo Kim, Hojin Chang, Bup Woo Kim, Chi Young Lim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The standard treatment regimen for locally recurrent lesions is total thyroidectomy, or complete removal of the recurrent thyroid lesion within the thyroid bed. However, reoperation increases the risk of complications and patients have to undergo general anesthesia. Percutaneous ethanol injection therapy represents a far less invasive procedure without general anesthesia and with lower risk of complications. Thirty-four patients who received PEIT at Yonsei University Medical Center between October 2002 and August 2009 for recurrent cervical nodal metastases of differentiated papillary thyroid cancer were included in this retrospective study. During a minimum follow-up of 60 months, treatment outcomes were determined by measuring the lesion size prior to the first injection and 3 months after the last injection. A total of 46 recurrent lesions were detected in 34 patients. Five patients underwent surgery and PEIT was administered to the remaining 19 and 22 lesions in the central compartment and lateral neck lymph nodes, respectively. Size increases were observed in seven (17.1%) lesions, whereas no changes in size and decreases were detected in 10 (24.4%) and 24 (58.5%) lesions. Patients with increased lymph nodes were significantly older (65.3 ± 14.4 vs. 48.2 ± 16.3 years; p = 0.02) and had smaller sizes (9.3 ± 1.0 vs. 12.3 ± 6.4 mm; p = 0.012). Although reoperation remains the first-line treatment for recurrent thyroid cancer, PEIT may be considered as a treatment option in selected patients with lesions larger than 1 cm who are ineligible for surgery or have refused reoperation.

Original languageEnglish
Pages (from-to)3497-3501
Number of pages5
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume274
Issue number9
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Ethanol
Injections
Reoperation
General Anesthesia
Thyroid Gland
Therapeutics
Lymph Nodes
Thyroidectomy
Thyroid Neoplasms
Papillary Thyroid cancer
Neck
Retrospective Studies
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Kim, S. Y., Kim, S. M., Chang, H., Kim, B. W., Lim, C. Y., Lee, Y. S., ... Park, C. S. (2017). Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. European Archives of Oto-Rhino-Laryngology, 274(9), 3497-3501. https://doi.org/10.1007/s00405-017-4660-2
Kim, Soo Young ; Kim, Seok Mo ; Chang, Hojin ; Kim, Bup Woo ; Lim, Chi Young ; Lee, Yong Sang ; Chang, Hang-Seok ; Park, Cheong Soo. / Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. In: European Archives of Oto-Rhino-Laryngology. 2017 ; Vol. 274, No. 9. pp. 3497-3501.
@article{81258f68263845b2aff3b75babd2dbc8,
title = "Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer",
abstract = "The standard treatment regimen for locally recurrent lesions is total thyroidectomy, or complete removal of the recurrent thyroid lesion within the thyroid bed. However, reoperation increases the risk of complications and patients have to undergo general anesthesia. Percutaneous ethanol injection therapy represents a far less invasive procedure without general anesthesia and with lower risk of complications. Thirty-four patients who received PEIT at Yonsei University Medical Center between October 2002 and August 2009 for recurrent cervical nodal metastases of differentiated papillary thyroid cancer were included in this retrospective study. During a minimum follow-up of 60 months, treatment outcomes were determined by measuring the lesion size prior to the first injection and 3 months after the last injection. A total of 46 recurrent lesions were detected in 34 patients. Five patients underwent surgery and PEIT was administered to the remaining 19 and 22 lesions in the central compartment and lateral neck lymph nodes, respectively. Size increases were observed in seven (17.1{\%}) lesions, whereas no changes in size and decreases were detected in 10 (24.4{\%}) and 24 (58.5{\%}) lesions. Patients with increased lymph nodes were significantly older (65.3 ± 14.4 vs. 48.2 ± 16.3 years; p = 0.02) and had smaller sizes (9.3 ± 1.0 vs. 12.3 ± 6.4 mm; p = 0.012). Although reoperation remains the first-line treatment for recurrent thyroid cancer, PEIT may be considered as a treatment option in selected patients with lesions larger than 1 cm who are ineligible for surgery or have refused reoperation.",
author = "Kim, {Soo Young} and Kim, {Seok Mo} and Hojin Chang and Kim, {Bup Woo} and Lim, {Chi Young} and Lee, {Yong Sang} and Hang-Seok Chang and Park, {Cheong Soo}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00405-017-4660-2",
language = "English",
volume = "274",
pages = "3497--3501",
journal = "Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde",
issn = "0003-9195",
publisher = "Springer Verlag",
number = "9",

}

Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. / Kim, Soo Young; Kim, Seok Mo; Chang, Hojin; Kim, Bup Woo; Lim, Chi Young; Lee, Yong Sang; Chang, Hang-Seok; Park, Cheong Soo.

In: European Archives of Oto-Rhino-Laryngology, Vol. 274, No. 9, 01.09.2017, p. 3497-3501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer

AU - Kim, Soo Young

AU - Kim, Seok Mo

AU - Chang, Hojin

AU - Kim, Bup Woo

AU - Lim, Chi Young

AU - Lee, Yong Sang

AU - Chang, Hang-Seok

AU - Park, Cheong Soo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The standard treatment regimen for locally recurrent lesions is total thyroidectomy, or complete removal of the recurrent thyroid lesion within the thyroid bed. However, reoperation increases the risk of complications and patients have to undergo general anesthesia. Percutaneous ethanol injection therapy represents a far less invasive procedure without general anesthesia and with lower risk of complications. Thirty-four patients who received PEIT at Yonsei University Medical Center between October 2002 and August 2009 for recurrent cervical nodal metastases of differentiated papillary thyroid cancer were included in this retrospective study. During a minimum follow-up of 60 months, treatment outcomes were determined by measuring the lesion size prior to the first injection and 3 months after the last injection. A total of 46 recurrent lesions were detected in 34 patients. Five patients underwent surgery and PEIT was administered to the remaining 19 and 22 lesions in the central compartment and lateral neck lymph nodes, respectively. Size increases were observed in seven (17.1%) lesions, whereas no changes in size and decreases were detected in 10 (24.4%) and 24 (58.5%) lesions. Patients with increased lymph nodes were significantly older (65.3 ± 14.4 vs. 48.2 ± 16.3 years; p = 0.02) and had smaller sizes (9.3 ± 1.0 vs. 12.3 ± 6.4 mm; p = 0.012). Although reoperation remains the first-line treatment for recurrent thyroid cancer, PEIT may be considered as a treatment option in selected patients with lesions larger than 1 cm who are ineligible for surgery or have refused reoperation.

AB - The standard treatment regimen for locally recurrent lesions is total thyroidectomy, or complete removal of the recurrent thyroid lesion within the thyroid bed. However, reoperation increases the risk of complications and patients have to undergo general anesthesia. Percutaneous ethanol injection therapy represents a far less invasive procedure without general anesthesia and with lower risk of complications. Thirty-four patients who received PEIT at Yonsei University Medical Center between October 2002 and August 2009 for recurrent cervical nodal metastases of differentiated papillary thyroid cancer were included in this retrospective study. During a minimum follow-up of 60 months, treatment outcomes were determined by measuring the lesion size prior to the first injection and 3 months after the last injection. A total of 46 recurrent lesions were detected in 34 patients. Five patients underwent surgery and PEIT was administered to the remaining 19 and 22 lesions in the central compartment and lateral neck lymph nodes, respectively. Size increases were observed in seven (17.1%) lesions, whereas no changes in size and decreases were detected in 10 (24.4%) and 24 (58.5%) lesions. Patients with increased lymph nodes were significantly older (65.3 ± 14.4 vs. 48.2 ± 16.3 years; p = 0.02) and had smaller sizes (9.3 ± 1.0 vs. 12.3 ± 6.4 mm; p = 0.012). Although reoperation remains the first-line treatment for recurrent thyroid cancer, PEIT may be considered as a treatment option in selected patients with lesions larger than 1 cm who are ineligible for surgery or have refused reoperation.

UR - http://www.scopus.com/inward/record.url?scp=85021732031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021732031&partnerID=8YFLogxK

U2 - 10.1007/s00405-017-4660-2

DO - 10.1007/s00405-017-4660-2

M3 - Article

VL - 274

SP - 3497

EP - 3501

JO - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

JF - Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde

SN - 0003-9195

IS - 9

ER -